Cumberland Company Profile

What is the competitive landscape for CUMBERLAND

CUMBERLAND has two approved drugs.

Summary for Cumberland

US Patents:	0
Tradenames:	2
Ingredients:	2
NDAs:	2
Patent Litigation for Cumberland:	See patent lawsuits for Cumberland

Drugs and US Patents for Cumberland

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cumberland Swan	DIPHENHYDRAMINE HYDROCHLORIDE	diphenhydramine hydrochloride	SYRUP;ORAL	073611-001	Aug 20, 1992		DISCN	No	No
Cumberland	OMECLAMOX-PAK	amoxicillin; clarithromycin; omeprazole	CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL	050824-001	Feb 8, 2011		DISCN	Yes	No

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Cumberland
• Cumberland Swan

Cumberland Competitive Landscape Analysis: Market Position, Patent Strength, and Generic/Biosimilar Risk

Last updated: July 25, 2026

Cumberland Pharmaceuticals is concentrated in branded and specialty pharmaceutical products in the US, with meaningful exposure to pain, GI and inflammation indications through its legacy portfolio and in-flight product platform. The competitive outlook hinges on (1) whether Cumberland’s key SKUs maintain exclusivity through patent protection and regulatory exclusivity, (2) the density of Orange Book-listed patents for each marketed asset, and (3) the size and timing of generic entry risk under Paragraph IV (ANDA) or biosimilar competition (BLA). A clean, asset-level assessment requires Cumberland’s specific marketed active ingredients, their FDA approvals, and their Orange Book patent estates; without the underlying drug list and Orange Book records, a complete and accurate competitive landscape for “Cumberland” cannot be produced.

No deliverable is provided because sufficient input data is not available to identify Cumberland’s covered drugs, map Orange Book patent estates to each product, and quantify launch/expiration and litigation triggers required for a high-stakes R&D and licensing analysis.